![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
25.50 | 2.65% | 987.00 | 994.50 | 1,004.00 | 1,013.00 | 958.00 | 1,001.00 | 973,842 | 16:35:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.09B | 2M | 0.0147 | 673.47 | 1.31B |
Date | Subject | Author | Discuss |
---|---|---|---|
09/7/2024 09:31 | I think the lesson here is not to dabble in drugs. | ![]() casholaa | |
09/7/2024 09:22 | the company claims that these are just temporary set backs | ![]() dealy | |
09/7/2024 09:22 | I wonder were the dust will settle though, you’d think the buybacks would be hammered now if it’s classed as cheap | ![]() ricky46 | |
09/7/2024 09:18 | Main product sales below forecasts. Secondary product which in the medium term was going to compensate for lower sales in the primary product now discontinued. Costs associated with the above. Litigation settled for an action they thought they would win. Ongoing multiple litigations. Potential litigation around Nasdaq listing (guaranteed I would think bearing in mind how close this statement is to the listing date). What's there to like...? | ![]() elsa7878 | |
09/7/2024 09:17 | I have re-read the update. It looks like the management are realistic and proactive. This is an over reaction | ![]() dealy | |
09/7/2024 09:16 | The directors selling at 1700 was always a concern for me.. lost and out here. Gla | ![]() swinsco | |
09/7/2024 08:53 | So on the 23/5 they reconfirm guidance, that was so they got the Nasdaq listing away as smooth as possible, then the share price drifts on a leaky ship, then 7 weeks later they drop all this news, terrible untrustworthy management in my opinion glad I sold out on the drift down, wish everyone the best of luck | ![]() ricky46 | |
09/7/2024 08:53 | Still some big profit targets. Given this was trading at 1800 recently this looks overdone? | ![]() gotabsirius | |
09/7/2024 08:40 | well, if the US listing was worth it or not , we will see today | ![]() dealy | |
09/7/2024 08:29 | All that money I had is now pretty much gone. I hope that the cmpany takes to the opportunity to buy back as many shares as it can at these prices. | ![]() casholaa | |
09/7/2024 08:24 | the company was buying its own shares even yesterday !!!! | ![]() dealy | |
09/7/2024 08:13 | it's down 50% over the last few weeks. is this bad news not fully priced in now? | ![]() dealy | |
09/7/2024 08:09 | Thought it would be worse to be fair. Horrendous update. | ![]() swinsco | |
09/7/2024 07:33 | Ouch Condolences | ![]() scepticalinvestor | |
09/7/2024 07:32 | Leaky ship | ![]() ricky46 | |
09/7/2024 07:29 | Now we know why it's been going down. | ![]() swinsco | |
09/7/2024 07:29 | Not looking forward to the opening price read this morning. A massive profit warning and Perseris discontinuation is going to keep shares weighed down. | ![]() hunter154 | |
09/7/2024 07:16 | Richmond, VA, July 9, 2024 - Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the Group's outlook for Q2 and FY 2024 financial performance, its product portfolio and litigation. Indivior is: · Updating Q2 net revenue (NR) expectations and FY 2024 guidance to reflect continued adverse market dynamics impacting near-term SUBLOCADE NR growth as well as the initial commercial adoption of OPVEE; At the mid-point, the Group continues to expect strong YOY NR growth for SUBLOCADE of 25% and YOY adjusted operating income growth of 12% in FY 2024; · Reiterating its medium-term financial outlook for double-digit NR growth and operating margin expansion, based on its confidence in achieving its intermediate and peak NR goals for SUBLOCADE as well as peak NR expectations for OPVEE; · Discontinuing sales and marketing for PERSERIS due to expected adverse impacts from increased payor management of the category that crystalized in Q2 and that are expected to make the product no longer financially viable; and, · Reaching a settlement agreement with end payor plaintiffs in the Health Care Services Corp (HCSC) consolidated cases to resolve the litigation for $85m. | ![]() la forge | |
08/7/2024 12:38 | They want to make their profit too. They can't do that without the share price taking a short term hit. | ![]() casholaa | |
08/7/2024 12:27 | Yanks waking up.. down it goes. lol. | ![]() swinsco | |
06/7/2024 17:48 | [...] www.marketbeat.com/i | ![]() the grumpy old men | |
06/7/2024 14:42 | Half year figures due within weeks according to my calculations . Whether that changes anything is another thing! | ![]() gregmorg | |
05/7/2024 14:39 | Nasdaq must open... down it goes. Haha. | ![]() swinsco |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions